Neskovic Nenad, Mandic Dario, Marczi Saska, Skiljic Sonja, Kristek Gordana, Vinkovic Hrvoje, Mraovic Boris, Debeljak Zeljko, Kvolik Slavica
Department of Anesthesiology, Resuscitation and ICU, Osijek University Hospital, Osijek, Croatia.
Faculty of Medicine, University Josip Juraj Strossmayer, Osijek, Croatia.
Front Pharmacol. 2021 Apr 15;12:656748. doi: 10.3389/fphar.2021.656748. eCollection 2021.
Most studies examining tramadol metabolism have been carried out in non-surgical patients and with oral tramadol. The aim of this study was 1) to measure concentrations of tramadol, -demethyltramadol (ODT), and -demethyltramadol (NDT) in the surgical patients admitted to the intensive care unit (ICU) within the first 24 postoperative hours after intravenous application of tramadol, and 2) to examine the effect of systemic inflammation on tramadol metabolism and postoperative pain. A prospective observational study was carried out in the surgical ICU in the tertiary hospital. In the group of 47 subsequent patients undergoing major abdominal surgery, pre-operative blood samples were taken for polymorphism analysis. Systemic inflammation was assessed based on laboratory and clinical indicators. All patients received 100 mg of tramadol intravenously every 6 h during the first postoperative day. Postoperative pain was assessed before and 30 min after tramadol injections. Tramadol, ODT, and NDT concentrations were determined by high-performance liquid chromatography. analysis revealed 2 poor (PM), 22 intermediate (IM), 22 extensive (EM), and 1 ultrafast metabolizer. After a dose of 100 mg of tramadol, t of 4.8 (3.2-7.6) h was observed. There were no differences in tramadol concentration among metabolic phenotypes. The area under the concentration-time curve at the first dose interval (AUC) of tramadol was 1,200 (917.9-1944.4) μg ×h ×L. NDT concentrations in UM were below the limit of quantification until the second dose of tramadol was administrated, while PM had higher NDT concentrations compared to EM and IM. ODT concentrations were higher in EM, compared to IM and PM. ODT AUC was 229.6 (137.7-326.2) μg ×h ×L and 95.5 (49.1-204.3) μg ×h ×L in EM and IM, respectively ( = 0.004). Preoperative cholinesterase activity (ChE) of ≤4244 U L was a cut-off value for a prediction of systemic inflammation in an early postoperative period. NDT AUC were significantly higher in patients with low ChE compared with normal ChE patients ( = 0.006). Pain measurements have confirmed that sufficient pain control was achieved in all patients after the second tramadol dose, except in the PM. polymorphism is a major factor in -demethylation, while systemic inflammation accompanied by low ChE has an important role in the -demethylation of tramadol in postoperative patients. Concentrations of tramadol, ODT, and NDT are lower in surgical patients than previously reported in non-surgical patients. Clinical Trial Registration: ClinicalTrials.gov, NCT04004481.
大多数关于曲马多代谢的研究是在非手术患者中使用口服曲马多进行的。本研究的目的是:1)测量术后24小时内入住重症监护病房(ICU)的手术患者静脉注射曲马多后,曲马多、O-去甲基曲马多(ODT)和N-去甲基曲马多(NDT)的浓度;2)研究全身炎症对曲马多代谢和术后疼痛的影响。在一家三级医院的外科ICU进行了一项前瞻性观察研究。在47例随后接受腹部大手术的患者组中,术前采集血样进行基因多态性分析。基于实验室和临床指标评估全身炎症。所有患者在术后第一天每6小时静脉注射100mg曲马多。在曲马多注射前和注射后30分钟评估术后疼痛。通过高效液相色谱法测定曲马多、ODT和NDT的浓度。基因分析显示有2例慢代谢者(PM)、22例中间代谢者(IM)、22例快代谢者(EM)和1例超快代谢者。给予100mg曲马多剂量后,观察到半衰期为4.8(3.2 - 7.6)小时。曲马多浓度在不同代谢表型之间没有差异。曲马多第一个剂量间隔的浓度 - 时间曲线下面积(AUC)为1200(917.9 - 1944.4)μg×h×L。超快代谢者(UM)中的NDT浓度在第二次给予曲马多之前低于定量限,而慢代谢者(PM)的NDT浓度高于快代谢者(EM)和中间代谢者(IM)。与IM和PM相比,快代谢者(EM)中的ODT浓度更高。EM组的ODT AUC为229.6(137.7 - 326.2)μg×h×L,IM组为95.5(49.1 - 204.3)μg×h×L(P = 0.004)。术前胆碱酯酶活性(ChE)≤4244 U/L是术后早期预测全身炎症的临界值。ChE低的患者与ChE正常的患者相比,NDT AUC显著更高(P = 0.006)。疼痛测量证实,除慢代谢者(PM)外,所有患者在第二次曲马多剂量后均实现了充分的疼痛控制。基因多态性是O-去甲基化的主要因素,而伴有低ChE的全身炎症在术后患者曲马多的N-去甲基化中起重要作用。手术患者中曲马多、ODT和NDT的浓度低于先前在非手术患者中的报道。临床试验注册:ClinicalTrials.gov,NCT04004481 。